Dainippon Lays Out R&D Table Ahead Of Latuda Challenges

Focus On Novel Schizophrenia Candidate

 
• By Ian Haydock

Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.

Schizophrenia
CNS Remains A Key Focus For Sumitomo Dainippon • Source: Shutterstock

More from Clinical Trials

More from R&D